Early Stage p53 Program Lands Ascenta $398M Deal with Sanofi
By Jennifer Boggs
Monday, June 7, 2010
In its first major collaboration since being founded in 2003, privately held Ascenta Therapeutics Inc. partnered an early stage cancer program with Sanofi-Aventis SA in exchange for up to $398 million in up-front and milestone payments, plus tiered royalties on any products that make it to market. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.